Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-TRBC1-CAR-CD3zeta-4-1BB-RQR8-expressing autologous T lymphocytes AUTO4

Autologous human T lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) containing an anti-T-cell receptor beta constant 1 (TRBC1; T-cell receptor beta-1 chain C region) single chain variable fragment (scFv) and the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Upon administration, anti-TRBC1-CAR-CD3zeta-4-1BB-RQR8-expressing autologous T lymphocytes AUTO4 targets and binds to the TRBC1 expressed on tumor cell surfaces. Subsequently, TRBC1-expressing tumor cells are lysed. In addition, AUTO4 carries the universal RQR8 safety "off" switch, which allows selective removal of the T-cells through both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) following administration of rituximab if unacceptable side-effects occur.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-TRBC1 CAR T cells AUTO4
RQR8/TRBC1 CAR T cells AUTO4
TRBC1-targeting CAR T cells AUTO4
Code name:AUTO 4
AUTO-4
AUTO4
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search